^99mTc‑labeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types.

ABSTRACT: The expression status of human epidermal growth factor receptor 2 (HER2) in cancer predicts response to HER2-targeted therapy. Therefore, its accurate determination is of utmost importance. In recent years, there has been an increase in research on noninvasive techniques for molecular imaging, as this method offers the advantages of a more accurate determination of HER2 status without the need for multiple biopsies. The technetium-labeled single-domain antibody RAD201, previously known as ^99mTc-NM-02, has been shown to be safe for use in breast cancer imaging with reasonable radiation doses, favorable biodistribution, and imaging characteristics.

Methods

A total of six HER2-positive, heavily pretreated patients with different cancer types aged between 42 and 69 years (5 w

SUBMITTER: Altunay B 

PROVIDER: S-EPMC9931776 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature